

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ABSTRACT (in English)	v
ABSTRACT (in Thai)	viii
LIST OF TABLES	xv
LIST OF FIGURES	xvii
ABBREVIATIONS	xix
CHAPTER I INTRODUCTION	1
CHAPTER II LITERATURE REVIEW	7
2.1 Biology of HIV	7
2.1.1 HIV morphology	8
2.1.2 HIV genomic structure	9
2.1.3 HIV viral replication	11
2.1.4 Classification and global distribution of HIV	13
2.2 HIV and AIDS	16
2.2.1 Epidemiology of HIV/AIDS	18
2.2.1.1 Global HIV/AIDS	18
2.2.1.2 HIV/AIDS in Asia	22
2.2.1.3 HIV/AIDS in Thailand	24
2.3 HIV/AIDS treatment and antiretroviral therapy (ART)	25
2.4 HIV drug resistance	30
2.4.1 Nucleoside and nucleotide analogues resistance	31
2.4.2 Nonnucleoside reverse transcriptase inhibitors (NNRTIs)	34

2.4.3	Protease inhibitors resistance	35
2.4.4	Fusion inhibitors resistance	36
2.4.5	Cross-resistance	36
2.5	HIV drug resistance testing methods	37
2.5.1	Genotypic assays	37
2.5.1.1	Standard direct sequencing	37
2.5.1.2	Single-genome sequencing (SGS)	38
2.5.2	Phenotypic assays	38
2.5.3	Virtual phenotype	39
2.5.4	Alternate assays	39
2.5.4.1	Allele-specific polymerase chain reaction (ASPCR)	40
2.5.4.2	Line probe assay (LiPA)	40
2.5.4.3	Oligonucleotide ligation assay (OLA)	41
CHAPTER III OBJECTIVES		44
CHAPTER IV RESEARCH DESIGN, MATERIALS AND METHODS		45
4.1	Research designs	45
4.2	Materials and Methods	45
4.2.1	Collection of clinical specimens	46
4.2.2	Collection of culture supernatant containing virus	46
4.2.3	Designing of primers to generate PCR product for OLA	47
4.2.4	Designing of OLA probes for M184V detection	47
4.2.5	Specimen preparation	48
4.2.5.1	RNA extraction	48
4.2.5.2	Reverse – transcription polymerase chain reaction	50
4.2.5.3	Nested polymerase chain reaction (Nested PCR)	51

4.2.5.4	DNA concentration measurement	51
4.2.6	Construction of reference plasmids	53
4.2.6.1	Transformation of recombinant plasmid DNA	54
4.2.6.2	Propagation and preparation of recombinant plasmid	55
4.2.6.3	Quantitation of the purified plasmid DNA	56
4.2.6.4	Confirmation of wild-type and mutant genotypes	56
4.2.6.4.1	Preparation of DNA sequencing reaction	56
4.2.6.4.2	Purification of sequencing products	57
4.2.6.4.3	Identification of DNA sequences	57
4.2.7	Optimization of the OLA condition	57
4.2.7.1	Oligonucleotide ligation assay (OLA)	58
4.2.7.2	Ligation reaction	59
4.2.7.3	Detection of the ligation products	59
4.2.8	Evaluation of the low detection limit of the mutant variant detection by OLA	60
4.2.9	Evaluation of the performance of the OLA with a small set of clinical specimens	62
4.2.10	Identification of indeterminate results	62
4.2.10.1	Purification of amplified PCR products	62
4.2.10.2	Nucleotide sequencing method	63
4.2.11	Data analysis	64
CHAPTER V RESULTS		65
5.1	Specimens for oligonucleotide ligation assay (OLA)	65
5.2	OLA primers and probes for M184V detection	66
5.3	Preparation specimens for OLA	69


5.4 Reference plasmids containing wild-type (184M) and mutant variants (184V)	71
5.5 Optimization of OLA conditions	80
5.6 The lower limit of detection of the mutant detection by OLA	88
5.7 Performance of OLA on small set of plasmid controls	90
5.8 Performance of OLA on clinical specimen testing	91
CHAPTER VI DISCUSSION	99
CHAPTER VI SUMMARY	107
REFERENCES	108
APPENDICES	123
Appendix A	125
Appendix B	127
Appendix C	132
Appendix D	133
Appendix E	134
CURRICULUM VITAE	138

LIST OF TABLES

Table	Page
1 Current HIV/AIDS situation in Thailand	25
2 Microplate preparation	52
3 Proportion of WT and MT for determination of lower limit of detection of OLA	61
4 Demographic characteristics of HIV-1 infected patients with treatment failure and HIV-1 M184V mutation data of 40 clinical specimens	65
5 Primers and probes for M184V detection	68
6 Nucleotide sequences of HIV-1 M184V wild-type and mutant plasmid controls	73
7 Detection of MT in the mixture of WT and MT at different concentration	89
8 Results of the performance evaluation of OLA and standard sequence analysis for the M184V mutation detection in known genotype plasmid DNA.	90
9 Interpretation of the detection of M184V mutation of HIV-1 in clinical specimens	93
10 Comparison of OLA and in-house sequence analysis for the detection M184V mutation	93
11 Evaluation of OLA and in-house sequence analysis for the detection of M184V mutation	94
12 The overall results of comparison of OLA-CRF01_AE with in-house sequence analysis for the M184V mutation detection	96

13 The nucleotide sequencing results of the specimens which had discordance results of HIV-1 M184V mutation between OLA and in-house HIV-1 genotypic drug resistant assay

98



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF FIGURES

Figure	Page
1 Structure of human immunodeficiency virus (HIV)	9
2 HIV-1 genomic structures	10
3 HIV replication	13
4 Global distributions of HIV-1 subtypes and recombinants	16
5 A generalized graph of the relationship between HIV copies number (viral load) and CD4 counts over the average course of untreated HIV infection	18
6 Global summary report of the AIDS epidemic, end 2009	20
7 Global report of number of adults and children to be living with HIV, end 2009	20
8 Global HIV trend, 1990-2009	21
9 Global report of AIDS statistics for Asia in 2001 and 2009	23
10 HIV prevalence among adults aged 15–49 years old in Asia, 1990-2009	23
11 Replication cycle of HIV and targets for antiretroviral therapy	26
12 Resistance by interference with the incorporation of a nucleoside analogue	32
13 Resistance by ATP-mediated excision of the nucleoside analogue	34
14 Mechanism of resistance of HIV to non-nucleoside reverse-transcriptase inhibitors (NNRTI)	35
15 Schematic presentation of OLA	43

16	Gel electrophoresis of the nested-PCR products of HIV-1 pol gene in the RT region that served as the template in the OLA	70
17	Gel electrophoresis of the amplification of HIV-1 plasmid DNA	72
18	An example of sequences alignment of HIV-1 184M-wild-type	74
19	An example of sequences alignment of HIV-1 184V-mutant	77
20	Optimization of DNA ligase enzyme concentration for HIV-1 M184V mutation detection by OLA with MT_184V probe system	82
21	Optimization of DNA ligase enzyme concentration for HIV-1 M184V mutation detection by OLA with Mod_MT184V probe system	83
22	Optimization of probes concentration for HIV-1 M184V mutation detection by OLA with MT_184V probe system	84
23	Optimization of probes concentration for HIV-1 M184V mutation detection by OLA with Mod_MT184V probe system	85
24	Optimization of templates concentration for HIV-1 M184V mutation detection by OLA with MT_184V probe system	86
25	Optimization of templates for HIV-1 M184V mutation detection by OLA with Mod_MT184V probe system	87
26	Determination of lower limit detection of OLA-CRF01_AE using mixture of mutant clones, CM028A or CM020, at different proportion in the background of wild-type clone (HM-12)	88
27	Detection of HIV-1 M184V mutation of HIV-1 in clinical specimens detection by OLA with Mod_MT184V probe system	92

ABBREVIATIONS

%	Percent
°C	Degree Celsius
µg	Microgram
µl	Microliter
3TC	Lamivudine
aa	Amino acid
Ab	Antibody
ABC	Abacavir
AIDS	Acquired Immunodeficiency Syndrome
ART	Antiretroviral therapy
ARV	Antiretroviral
ATV	Atazanavir
AZT	Zidovudine (also known as ZDV)
bp	Basepair
CA	Capsid protein
CCR5	CC-chemokine receptor 5
CD	Cluster of differentiation
CD4 cell	T-lymphocyte bearing CD4 receptor
CIA	Central Intelligent Agency
CMV	cytomegalovirus

CRFs	Circulating recombinant forms
CSWs	Commercial sex workers
CXCR4	CXC-chemokine receptor 4
d4T	Stavudine
ddI	Didanosine
DNA	Deoxyribonucleic acid
dATP	Deoxyadenosine triphosphate
dCTP	Deoxycytidine triphosphate
dGTP	Deoxyguanosine triphosphate
dNTPs	Deoxynucleoside triphosphates
dTTP	Deoxythymidine triphosphate
EDTA	Ethylenediamine tetraacetic acid
EFV	Efavirenz
EIA	Enzyme immunoassay
ELISA	Enzyme-linked immunosorbent assay
ENV	Envelope
ETV	Etravirine
FSW	Female sex workers
FTC	Emtricitabine
GAG	Group specific antigens
gp	Glycoprotein
GRADE	Grading of recommendations assessment, development and evaluation
HAART	Highly active antiretroviral therapy
HIV	Human immunodeficiency virus

HIVDR	HIV drug resistance
HIV RNA	Human immunodeficiency virus ribonucleic acid
HLA	Human leukocyte antigens
IDU	Injecting drug users
IDV	Indinavir
IN	Integrase
kb	Kilobase
KCl	Potassium chloride
Kg	Kilogram
LPV	Lopinavir
LPV/r	Lopinavir/ritonavir
LTR	Long terminal repeat
M	Major
M	Molar
MA	Matrix protein
mg	Miligram
MgCl ₂	Magnesium chloride
MHC	Major histocompatibility complex
min	Minute
ml	Milliliter
mM	Millimolar
MOPH	Ministry of Public Health
MSM	Men who have sex with men
MTCT	Mother to child transmission
N	New, or non-M, non-O

NAM	Nucleoside/nucleotide analogue mutation
NAP	National AIDS program
NAPHA	National access to antiretroviral program for PHA
NFV	Nelfinavir
NGO	Non-government organization
ng	Nanogram
NIH	National Institutes of Health
nm	Nanometer
NNRTI	Non-nucleoside reverse transcriptase inhibitor
NRTI	Nucleoside reverse transcriptase inhibitor
NVP	Nevirapine
O	Outlier
O.D.	Optical density
PCP	<i>Pneumocystis carinii</i> Pneumonia
PCR	Polymerase chain reaction
PEP	Post exposure prophylaxis
PHA	People who have AIDS
PHPT	Perinatal HIV Prevention Trial
PI	Protease inhibitor
PLHIV	People living with HIV
pmol	Picomole
PMTCT	Prevention of mother – to – child HIV transmission
Pol	Polymerase
PR	Protease
RNA	Ribonucleic acid

rpm	Revolutions per minute
REV	Regulatory factor for HIV expressing
RT	Reverse transcriptase
RT-PCR	Reverse transcriptase-polymerase chain reaction
RTV	Ritonavir
sec	Second
SQV	Saquinavir
STI	Sexually transmitted disease
TAT	Transactivator of transcription
TB	Tuberculosis
TDF	Tenofovir disoproxil fumarate
T _m	Melting temperature
Tris-HCl	Tris-hydroxymethyl aminomethane hydrochloride
U	Unit
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNGASS	United Nations General Assembly Special Session on HIV/AIDS
USA	United State of America
USAID	United States Agency for International Development
VIF	Viral infectivity factor
VL	Viral load
VPR	Viral protein R
VPU	Viral protein U
WHO	World Health Organization